Thomas Chalberg

Genascence Corp. develops gene therapy products for musculoskeletal diseases. The company was founded by Dr. Annahita Keravala and Dr. Thomas W. Chalberg in 2017 and is headquartered in Palo Alto, CA.

ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation.

Chameleon Biosciences, Inc. engages in the provision of a pre-clinical stage gene therapy. The company was founded by Genine Winslow and Jeffery Scott Vick and is headquartered in Berkeley, CA.

SightGlass Vision, Inc. is an American clinical-stage life sciences company that focuses on ending nearsightedness in children. The private company is based in California and is developing innovative spectacle lenses based on groundbreaking research from the University of Washington. The company's unique diffusion optics technology is aimed at reducing the progression of myopia in children. SightGlass Vision was founded in 2016 by professors Jay and Maureen Neitz, Dr. James Kuchenbecker, and Dr. Thomas Chalberg, who is the CEO of the company.

Verana Health, Inc. engages in the development of software solutions for remote patient monitoring and data analytics. It focuses on bridging the gap between healthcare providers and patients with mobile tests. The company was founded by Mark S. Blumenkranz and Daniel V. Palanker in 2008 and is headquartered in San Francisco, CA.